List of Vaccines Companies in Australia - 14

Anteris Technologies is a structural heart company focused on developing innovative solutions to the biggest challenges facing aortic stenosis patients and their physicians. Our DurAVR™ Transcatheter Heart Valve (THV) System is designed for younger patients who need a heart valve that will last their lifetime. DurAVR™ THV is a unique, single-piece valve and its first-in-class biomimetic design replicates the normal blood flow of a healthy human aortic valve. | $AVR | ASX: AVR | #DurAVR #ADAPT #structuralheart #TAVR #TAVI #cardiology

BioDiem is a biopharmaceutical company that focuses on developing and commercialising vaccines and infectious disease therapies.

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, CSL Plasma and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

Finding solutions to prevent, treat and cure infectious diseases and understanding the complexities of microbes and the immune system requires innovative approaches and concentrated effort. This is why The University of Melbourne – a world leader in education, teaching and research excellence – and The Royal Melbourne Hospital – an internationally renowned institution providing outstanding care, research and learning –partnered to create the Peter Doherty Institute for Infection and Immunity (Doherty Institute); a centre of excellence where leading scientists and clinicians collaborate to improve human health globally. Located in the heart of Melbourne's Biomedical Precinct, the Doherty Institute is named in honour of Patron, Laureate Professor Peter Doherty, winner of the 1996 Nobel Prize in Physiology or Medicine for discovering how the immune system recognises virus-infected cells. Under the expert guidance of Director, University of Melbourne Professor Sharon Lewin, a leader in research and clinical management of HIV and infectious diseases, the Doherty Institute has more than 700 staff who work on infection and immunity through a broad spectrum of activities. This includes discovery research; diagnosis, surveillance and investigation of infectious disease outbreaks; and the development of ways to prevent, treat and eliminate infectious diseases.

Gamma Vaccines Pty is a biotechnology company that specializes in developing a 'universal' cross-protective influenza virus vaccine called Gamma-Flu®.

GPN Vaccines is a biotechnology company developing a Streptococcus pneumoniae vaccine. S. pneumoniae is a major pathogen found largely in the respiratory tract, and there are 100 known serotypes of S. pneumoniae. The company is focused on developing a broad-spectrum vaccine against Streptococcus pneumoniae, which causes life-threatening pneumonia and meningitis. GPN Vaccines has reported positive safety and immunogenicity data from its phase 1 trial of Gamma-PN™, a proprietary engineered whole-cell vaccine against Streptococcus pneumoniae.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. ACCEPTABLE USE POLICY We welcome your comments on our page but we ask that you help us comply with the Therapeutic Goods Advertising Code. Please consider these guidelines before commenting. We will remove any comments that may result in us breaching the Code. We love when you comment and tag your friends and family on our posts but we ask that you do not: • endorse our product if you are: o an employee or contractor of a government authority, a hospital or a healthcare facility o a health practitioner, health professional or medical researcher o involved with the production, sale, supply or marketing of our product o not using your own name on this social media platform • imply that a government authority, a hospital or a healthcare facility endorse our product • make comments about how a product works for you outside of its intended purpose, as these comments can be dangerous or misleading - our products are developed for particular purposes, as stated on the label and/or in our advertising • make comments about serious conditions, diseases, ailments or defects, such as comments about how a product helped with your treatment of a serious disease or how it will relieve a tagged person's serious condition We also have an obligation to make sure any advertisements we make, including endorsements and testimonials, are not misleading. Therefore we promise to disclose: • where a person has been, or will be, compensated for making a testimonial • where we have actors making the testimonial, such as in cases where the original person who made the testimonial does not want to appear in our advertisement • where the person making the testimonial is an immediate family member of anyone employed by our company.

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies.

InterK Peptide Therapeutics functions largely as a virtual company and located in Sydney, Australia.The company’s R&D program is supported by Contract Research Organisations located within Australia and overseas. All three assets share the ability to inhibit cancer growth in vivo in murine models but also differ significantly in their respective immunomodulating effects on expression of cytokines, cytokine receptors and regulation of signalling pathways within T cells, natural killer cells and antigen-presenting cells.

Island Pharmaceuticals is a drug research and repurposing company, focused on developing preventative or therapeutic drugs for viral infections. We have a lead asset – ISLA-101 - that was initially developed by our wholly owned subsidiary, Isla Pharmaceuticals. ISLA-101 is a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

Delivery system for recombinant protein vaccine

Sementis Ltd is an Australian unlisted public biotechnology company based in Adelaide, South Australia and dedicated to research and development of new vaccines to tackle viruses and diseases globally. Sementis conducts it's research and development activities in partnership with the University of South Australia. We are using our proprietary Sementis Copenhagen Vector (SCV) and associated manufacturing system for the rapid development of effective vaccines to tackle infectious diseases of highest unmet medical needs as well as vaccines for pandemic preparedness. Our vaccine technology is also under evaluation for the prevention of allergies, with potential future applications also in cancer. Our lead vaccine candidates including a combination Zika-Chikungunya vaccine, a 'second generation' COVID-19 vaccine and therapeutic vaccine for peanut allergy. The SCV system couples a genetically engineered, non-replicative viral vector with a genetically engineered commercial manufacturing cell-line. The genes of disease antigens can be easily added to the viral vector, allowing for rapid adaptation of the vaccine against a single or multiple diseases and then manufacture on a commercial scale. The SCV is derived from a vaccinia virus strain used to eradicate smallpox, and concerns about safety have been addressed through our targeted genetic attenuation, thus making SCV vectored vaccines safe for use. Vaccines made using SCV are grown in our proprietary Chinese Hamster Ovary (CHO) cells, an industry standard cell line for large scale manufacturing with high yield and consistent batch quality. Extensive advanced pre-clinical studies have shown that vaccines using the SCV platform are safe and efficacious after a single vaccination, eliciting potent T and B-cell immunity, and long lasting protective vaccine immune response. We are now focussed on final GLP toxicology and immunogenicity studies in preparation for first in-human Phase I clinical trials.

In collaboration with RMIT University, Snoretox is developing the world’s first injectable solution to treat obstructive sleep apnoea and other conditions involving low muscle tone. Our game-changing technology is based on molecules of tetanus toxin, modified to ensure they work around the tetanus vaccine. Just as Botox uses tiny amounts of botulinum toxin to relax muscles, our prototype therapeutic uses minute amounts of safe modified tetanus toxin to achieve the opposite effect – muscle toning.

Vaxine was incorporated in 2002 as an Australian biotechnology company focussing on development of innovative vaccine technologies, with its lead product being its Advax delta inulin adjuvant. Supported by funding contracts from the National Institutes of Health Vaxine has developed a broad range of vaccines, all utilizing its Advax adjuvant technology for enhanced immunogenicity and protection. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, COVID-19, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy. Vaxine also has a veterinary division that is commercialising vaccine adjuvants tailored to specific animal health problems.